Literature DB >> 26285074

Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa.

Paul L A M Corstjens1, Elisa M Tjon Kon Fat2, Claudia J de Dood2, Jolien J van der Ploeg-van Schip3, Kees L M C Franken3, Novel N Chegou4, Jayne S Sutherland5, Rawleigh Howe6, Adane Mihret6, Desta Kassa7, Marieta van der Vyver8, Jacob Sheehama8, Felanji Simukonda9, Harriet Mayanja-Kizza10, Tom H M Ottenhoff3, Gerhard Walzl4, Annemieke Geluk3.   

Abstract

OBJECTIVE: Multi-center evaluation of a user-friendly lateral flow test for detection of IP-10 and CCL4 levels in Mycobacterium tuberculosis (Mtb) antigen-stimulated whole blood samples from tuberculosis (TB) suspects. DESIGN AND METHODS: A quantitative lateral flow (LF)-based assay platform was applied to detect chemokines IP-10 and CCL4. Chemokine quantitation was achieved using interference-free, fluorescent up-converting phosphor (UCP) labels. The new assays allowed worldwide shipping and storage without requiring a cold chain and were tested at seven institutes (including Ethiopia, Malawi, The Gambia, South Africa, Uganda and Namibia) employing portable lightweight readers for detection of the UCP label. At each site, clinical samples, confirmed TB and non-TB (i.e. other respiratory diseases (ORD)) cases, were collected and analyzed simultaneously with quality control (QC) human IP-10 or CCL4 standards.
RESULTS: Performance of the UCP-LF assay in Africa using QC standards indicated high robustness allowing quantitative detection between 100 and 100,000pg/mL. The optimized assays allowed successful determination of chemokine levels using 1μL whole blood sample from the locally recruited subjects with TB or ORD.
CONCLUSION: This African multi-center trial further demonstrated the applicability of the low-tech and robust UCP-LF platform as a convenient quantitative assay for chemokine detection in whole blood. Ambient shipping and storage of all assay reagents and the availability of lightweight standalone readers were acknowledged as essential requirement for test implementation in particular in remote and resource-limited settings.
Copyright © 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CCL4; Chemokine; Diagnosis, field-friendly, lateral flow; IP-10; Tuberculosis; Up-converting phosphor, UCP

Mesh:

Substances:

Year:  2015        PMID: 26285074     DOI: 10.1016/j.clinbiochem.2015.08.013

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  20 in total

Review 1.  Inorganic Complexes and Metal-Based Nanomaterials for Infectious Disease Diagnostics.

Authors:  Christine F Markwalter; Andrew G Kantor; Carson P Moore; Kelly A Richardson; David W Wright
Journal:  Chem Rev       Date:  2018-12-04       Impact factor: 60.622

2.  Field-Friendly Test for Monitoring Multiple Immune Response Markers during Onset and Treatment of Exacerbated Immunity in Leprosy.

Authors:  Paul L A M Corstjens; Anouk van Hooij; Elisa M Tjon Kon Fat; Susan J F van den Eeden; Louis Wilson; Annemieke Geluk
Journal:  Clin Vaccine Immunol       Date:  2016-06-06

3.  Longitudinal IP-10 Serum Levels Are Associated with the Course of Disease Activity and Remission in Patients with Rheumatoid Arthritis.

Authors:  Anouk van Hooij; Debbie M Boeters; Elisa M Tjon Kon Fat; Susan J F van den Eeden; Paul L A M Corstjens; Annette H M van der Helm-van Mil; Annemieke Geluk
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

4.  Prospective evaluation of host biomarkers other than interferon gamma in QuantiFERON Plus supernatants as candidates for the diagnosis of tuberculosis in symptomatic individuals.

Authors:  Portia M Manngo; Andrea Gutschmidt; Candice I Snyders; Hygon Mutavhatsindi; Charles M Manyelo; Nonjabulo S Makhoba; Petri Ahlers; Andriette Hiemstra; Kim Stanley; Shirley McAnda; Martin Kidd; Stephanus T Malherbe; Gerhard Walzl; Novel N Chegou
Journal:  J Infect       Date:  2019-07-15       Impact factor: 6.072

5.  Diagnostic Potential of Novel Salivary Host Biomarkers as Candidates for the Immunological Diagnosis of Tuberculosis Disease and Monitoring of Tuberculosis Treatment Response.

Authors:  Ruschca Jacobs; Elizna Maasdorp; Stephanus Malherbe; Andre G Loxton; Kim Stanley; Gian van der Spuy; Gerhard Walzl; Novel N Chegou
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

Review 6.  Tuberculosis Biomarkers: From Diagnosis to Protection.

Authors:  Delia Goletti; Elisa Petruccioli; Simone A Joosten; Tom H M Ottenhoff
Journal:  Infect Dis Rep       Date:  2016-06-24

7.  Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response.

Authors:  Ruschca Jacobs; Stephanus Malherbe; Andre G Loxton; Kim Stanley; Gian van der Spuy; Gerhard Walzl; Novel N Chegou
Journal:  Oncotarget       Date:  2016-09-06

8.  Field-friendly serological tests for determination of M. leprae-specific antibodies.

Authors:  Anouk van Hooij; Elisa M Tjon Kon Fat; Susan J F van den Eeden; Louis Wilson; Moises Batista da Silva; Claudio G Salgado; John S Spencer; Paul L A M Corstjens; Annemieke Geluk
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

9.  IP-10 Kinetics in the First Week of Therapy are Strongly Associated with Bacteriological Confirmation of Tuberculosis Diagnosis in HIV-Infected Patients.

Authors:  Alberto L García-Basteiro; Edson Mambuque; Alice den Hertog; Belén Saavedra; Inocencia Cuamba; Laura Oliveras; Silvia Blanco; Helder Bulo; Joe Brew; Luis E Cuevas; Frank Cobelens; Augusto Nhabomba; Richard Anthony
Journal:  Sci Rep       Date:  2017-10-30       Impact factor: 4.379

10.  Quantitative lateral flow strip assays as User-Friendly Tools To Detect Biomarker Profiles For Leprosy.

Authors:  Anouk van Hooij; Elisa M Tjon Kon Fat; Renate Richardus; Susan J F van den Eeden; Louis Wilson; Claudia J de Dood; Roel Faber; Korshed Alam; Jan Hendrik Richardus; Paul L A M Corstjens; Annemieke Geluk
Journal:  Sci Rep       Date:  2016-09-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.